Novo Nordisk’s investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026
Screenshot preview · Scroll to view the full email
Archived for design inspiration. Original email and brand assets belong to their respective owners. Design observations describe the creative; they are not campaign results.
More emails like this
Explore other emails with shared design, campaign, or industry tags.
Novo NordiskView brand email archive
